Novo Reports 25% Mean Weight Loss Among Early CagriSema Responders
Novo Nordisk said a post hoc analysis of the REDEFINE 1 trial presented at ObesityWeek 2026 found CagriSema was associated with 25% mean weight loss among early responders.
Novo Nordisk said a post hoc analysis of the REDEFINE 1 trial presented at ObesityWeek 2026 found CagriSema was associated with 25% mean weight loss among early responders.